ADVM Quote, Trading Chart, Adverum Biotechnologies Inc.
home / stock / advm / advm quote
$10.96 Last:
-3.01% Change Percent:
$11.3 Open:
$10.96 Previous Close:
$11.86 High:
$10.59 Low:
1,350,233 Volume:
03/04/2021 04:55:14 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-04 | 11.3 | 10.96 | 11.86 | 10.59 | 1,350,233 |
| 2021-03-03 | 12.17 | 11.3 | 12.4323 | 11.29 | 850,316 |
| 2021-03-02 | 13.02 | 12.15 | 13.16 | 12.15 | 671,437 |
| 2021-03-01 | 13 | 13.32 | 13.46 | 12.85 | 863,412 |
| 2021-02-26 | 12.61 | 12.83 | 12.9897 | 12 | 1,250,643 |
| 2021-02-25 | 13.12 | 12.52 | 13.3676 | 12.47 | 658,822 |
| 2021-02-24 | 13.46 | 13.29 | 13.88 | 13.1 | 630,431 |
| 2021-02-23 | 12.01 | 13.33 | 13.39 | 11.96 | 1,447,838 |
| 2021-02-22 | 12.75 | 12.5 | 12.85 | 12.42 | 508,626 |
| 2021-02-19 | 12.83 | 12.85 | 13.4819 | 12.79 | 397,868 |
| 2021-02-18 | 13.24 | 12.84 | 13.24 | 12.51 | 500,633 |
| 2021-02-17 | 13.27 | 13.31 | 13.74 | 12.97 | 651,291 |
| 2021-02-16 | 13.45 | 13.44 | 13.73 | 13.14 | 563,160 |
| 2021-02-15 | 13.7 | 13.43 | 14.28 | 13.14 | 757,109 |
| 2021-02-12 | 13.7 | 13.43 | 14.28 | 13.14 | 756,825 |
| 2021-02-11 | 14.02 | 13.88 | 14.1 | 13.51 | 449,859 |
| 2021-02-10 | 14.1 | 13.77 | 14.6 | 13.6501 | 523,601 |
| 2021-02-09 | 14.45 | 14.24 | 14.57 | 14.13 | 493,506 |
| 2021-02-08 | 14.23 | 14.36 | 14.55 | 14.08 | 729,304 |
| 2021-02-05 | 13.825 | 14.01 | 14.03 | 13.6 | 689,672 |
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Adverum Biotechnologies, Inc. (NASDAQ: ADVM) Q4 2020 Earnings Call Mar 1, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Adverum Biotechnologies, Inc. (ADVM) Q4 2020 Earnings Call Tra...
-
-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA -- -- Two global Phase 3 trials expected to enroll 900 patients in total; Targeted to initiate in 4Q 2021 -- -- Company t...
-
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, March 1, 2021 at ...